SecBot SecBot
8-K ·Filed Aug 18, 2026

TCRX

TScan Therapeutics, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001193125-26-355664
8-K material event: Items 1.02
Actionable Insight ▼ Bearish

The termination removes a major source of potential future revenue and validation for TScan's platform, increasing reliance on its internal pipeline. Traders should watch for the company's next update on cash runway and pipeline progress, as the loss of this partnership may accelerate cash burn concerns.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.7500
T+0 close · Aug 18, 2026 · via day close
Latest settled
−77.60%
T+60 · $0.1680
Vs SPY
−76.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 19 $0.7500entry
  2. T+1 · 3mo ago +3.49%α +4.33% · $0.7762
  3. T+5 · 3mo ago +3.65%α +4.04% · $0.7774
  4. T+20 · 2mo ago −55.53%α −53.58% · $0.3335
  5. T+60 · 5d ago −77.60%α −76.05% · $0.1680
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TScan Therapeutics disclosed that Amgen terminated their Research Collaboration and License Agreement for Crohn's disease, effective November 10, 2026. This ends a partnership that included a $30M upfront payment (received in 2023) and over $500M in potential milestones, with no termination penalty owed by TScan. The loss of future milestone and royalty revenue is a material negative for the company, which has a $50M market cap and no approved products.

Key Facts

  • Amgen terminated the Research Collaboration and License Agreement with TScan Therapeutics on August 12, 2026, effective November 10, 2026.
  • No early termination penalty is payable by TScan in connection with the termination.
  • The agreement provided for a non-refundable upfront payment of $30.0 million (received in 2023), success-based milestone payments of over $500 million in aggregate, and tiered single-digit royalty payments.
  • TScan is obligated to wind down its activities under the research plan; licenses granted under the agreement will terminate.
  • TScan does not expect to receive future milestone or royalty payments unless Amgen continues to exploit product candidates.

Financial Impact

Loss of potential future milestone payments exceeding $500 million and tiered single-digit royalties on net sales; no termination fee received.

revenuemilestone paymentsroyalties

Risk Factors

  • Loss of a major partnership with Amgen removes a key value driver and potential revenue stream.
  • TScan's reliance on its internal pipeline increases, with no guarantee of clinical or regulatory success.
  • The company's $50M market cap and pre-revenue status make it highly sensitive to this setback.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
77% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-355664
Document: 0001193125-26-355664-index-headers.html0001193125-26-355664
Document: 0001193125-26-355664-index.html0001193125-26-355664
Document: 0001193125-26-355664.txt0001193125-26-355664

Track record

15 reports on TCRX

Performance horizon

6 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +76.48% at T+60 after the Aug 12, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
  2. Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
  3. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
  4. Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
  5. Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
  6. Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
  7. Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
  8. Aug 18, 202612w ago 8-K Bearish 7/10 Viewing Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 6/10 No price data
  10. Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 18, 2026